CNBC's Meg Tirrell speaks to Bristol-Myers CEO Giovanni Caforio about his company's earnings and outlook, August drug trial results, the election and potential M&A. » Read More
By: Dan Mangan
The deal requires Mylan to pay $465 million to settle claims the company shortchange Medicaid on EpiPen rebates. » Read More
CNBC's Meg Tirrell reports the latest trouble in the biotech sector, specifically involving Illumina and Theranos.
Illumina shares sink after the company trimmed its third-quarter revenue projections.
Rich Ross, Evercore ISI, goes off the charts to take a look at three stocks set for a breakout.
Michael Yee, RBC Capital Markets biotech analyst, shares his take on big biotech movers including Mylan, Tesaro and more.
CNBC's Meg Tirrell reports the latest in biotech, including what is next for Mylan following the company's EpiPen settlement with the U.S. Department of Justice.
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
CNBC's Meg Tirrell reports on the moves in cancer drugmakers following the European Cancer Congress in Copenhagen. The "FMHR" traders weigh in.
Elliot Wilbur, Raymond James, discusses his call to upgrade Mylan to buy based on valuation.
Raymond James on Monday upgraded shares of Mylan to strong buy from market perform, citing valuations that have reached a multidecade low.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
Mylan agreed Friday to a $465 million settlement over the classification of its anti-allergy EpiPen auto-injector under the Medicaid Drug Rebate program.
CNBC's Meg Tirrell reports the latest on Mylan's EpiPen classification and rebate through Medicaid.
Goldman Sachs initiated coverage of GW Pharmaceuticals with a buy rating.
Bristol-Myers Squibb's approach to treating lung cancer will have a chance to redeem itself when new data comes out on Sunday.
It's not clear when EpiPen owner Mylan was told by health officials it was misclassifying the anti-allergy device for rebate purposes.
Dengvaxia, the world's first dengue vaccine, has already been approved in 11 countries, including four in Asia, says Sanofi Pasteur's Ng Su Peing.
Get the best of CNBC in your inbox